Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

To study the immune response to prostate cancer, we developed an autochthonous animal model based on the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse in which spontaneously developing tumors express influenza hemagglutinin as a unique, tumor-associated antigen. Our prior studies in these animals showed immunologic tolerance to hemagglutinin, mirroring the clinical situation in patients with cancer who are generally nonresponsive to their disease. We used this physiologically relevant animal model to assess the immunomodulatory effects of cyclophosphamide when administered in combination with an allogeneic, cell-based granulocyte-macrophage colony-stimulating factor-secreting cancer immunotherapy. Through adoptive transfer of prostate/prostate cancer-specific CD8 T cells as well as through studies of the endogenous T-cell repertoire, we found that cyclophosphamide induced a marked augmentation of the antitumor immune response. This effect was strongly dependent on both the dose and the timing of cyclophosphamide administration. Mechanistic studies showed that immune augmentation by cyclophosphamide was associated with a transient depletion of regulatory T cells in the tumor draining lymph nodes but not in the peripheral circulation. Interestingly, we also noted effects on dendritic cell phenotype; low-dose cyclophosphamide was associated with increased expression of dendritic cell maturation markers. Taken together, these data clarify the dose, timing, and mechanism of action by which immunomodulatory cyclophosphamide can be translated to a clinical setting in a combinatorial cancer treatment strategy.

[1]  A. Liston,et al.  Regulatory T Cells , 2011, Methods in Molecular Biology.

[2]  Jianzhu Chen,et al.  Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice , 2008, Proceedings of the National Academy of Sciences.

[3]  Shimon Sakaguchi,et al.  Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation , 2008, Proceedings of the National Academy of Sciences.

[4]  P. Youinou,et al.  Regulatory B lymphocytes in humans: a potential role in autoimmunity. , 2008, Arthritis and rheumatism.

[5]  C. Drake.  Immunotherapy for metastatic prostate cancer. , 2008, Urologic oncology.

[6]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[7]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[8]  E. Jaffee,et al.  Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine , 2008 .

[9]  A. Riker,et al.  Comparative methodologies of regulatory T cell depletion in a murine melanoma model. , 2008, Journal of immunological methods.

[10]  E. Jaffee,et al.  Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation , 2008, Clinical Cancer Research.

[11]  D. Getnet,et al.  LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. , 2007, The Journal of clinical investigation.

[12]  T. Gajewski.  Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment , 2007, Clinical Cancer Research.

[13]  D. Getnet,et al.  Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. , 2007, Blood.

[14]  D. McNeel.  Prostate cancer immunotherapy , 2007, Current opinion in urology.

[15]  J. Yewdell,et al.  Viral Alteration of Cellular Translational Machinery Increases Defective Ribosomal Products , 2007, Journal of Virology.

[16]  M. Anderson,et al.  Tolerization of Tumor-Specific T Cells Despite Efficient Initial Priming in a Primary Murine Model of Prostate Cancer1 , 2007, The Journal of Immunology.

[17]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[18]  J. Simons,et al.  Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. , 2006, Urologic oncology.

[19]  S. Quezada,et al.  CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. , 2006, The Journal of clinical investigation.

[20]  R. Matusik,et al.  T‐cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction , 2006, The Prostate.

[21]  J. Gulley,et al.  Therapeutic vaccines for prostate cancer. , 2006, The oncologist.

[22]  E. Small,et al.  Immunotherapy for prostate cancer , 2001, Current urology reports.

[23]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[24]  R. DiPaola,et al.  Pox viral vaccine approaches. , 2005, Seminars in oncology.

[25]  E. Jaffee,et al.  Immunotherapy for pancreatic cancer — science driving clinical progress , 2005, Nature Reviews Cancer.

[26]  A. Viola,et al.  Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers , 2005, The Journal of experimental medicine.

[27]  Donna Niedzwiecki,et al.  Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1 , 2005, The Journal of Immunology.

[28]  C. Drake,et al.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. , 2005, Cancer cell.

[29]  N. Greenberg,et al.  Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization , 2005, European journal of immunology.

[30]  H. von Boehmer,et al.  Mechanisms of suppression by suppressor T cells , 2005, Nature immunology.

[31]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[32]  D. Pardoll,et al.  Cancer immunotherapy: breaking the barriers to harvest the crop , 2004, Nature Medicine.

[33]  R. Hruban,et al.  Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.

[34]  E. Jaffee,et al.  A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. , 2004, Human gene therapy.

[35]  Javier Hernández,et al.  Deletion of Naive CD8 T Cells Requires Persistent Antigen and Is Not Programmed by an Initial Signal from the Tolerogenic APC 1 , 2003, The Journal of Immunology.

[36]  Tsuey-Ming Chen,et al.  Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.

[37]  D. Pardoll,et al.  Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. , 2003, Blood.

[38]  M. Bevan,et al.  Constitutive versus Activation-dependent Cross-Presentation of Immune Complexes by CD8+ and CD8− Dendritic Cells In Vivo , 2002, The Journal of experimental medicine.

[39]  B. Sandmaier,et al.  Theratope® vaccine (STn-KLH) , 2001, Expert opinion on biological therapy.

[40]  N. Greenberg,et al.  Autochthonous mouse models for prostate cancer: past, present and future. , 2001, Seminars in cancer biology.

[41]  E. Jaffee,et al.  Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. , 2001, Cancer research.

[42]  P. Klenerman,et al.  A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. , 2001, Journal of immunological methods.

[43]  M. Bevan,et al.  Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo , 2000, The Journal of experimental medicine.

[44]  E. Sotomayor,et al.  A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. , 1999, Human gene therapy.

[45]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Foster,et al.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.

[47]  H. Mcdevitt,et al.  CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. , 1996, Journal of immunology.

[48]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Maguire,et al.  Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. , 1986, Cancer research.

[50]  R. North.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.

[51]  H. Maguire,et al.  Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. , 1967, The Journal of investigative dermatology.